Beauchamp, Geetha
Donnell, Deborah
Hosek, Sybil
Anderson, Peter L.
Chan, Kwun C. G.
Dye, Bonnie J.
Mgodi, Nyaradzo
Bekker, Linda-Gail
Delany-Moretlwe, Sinead
Celum, Connie
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (UM1AI068619, UM1AI068619)
Article History
Received: 6 February 2023
Accepted: 9 May 2023
First Online: 19 May 2023
Declarations
:
: The HPTN 082 study received Institutional Review Board approval from each study site, the University of Washington, and the University of California—San Francisco. All methods were carried out in accordance with IRB approval, country, and local regulations. All participants provided written informed consent in English or in their preferred local language. Following local regulations, participants below the legal age for consent (age < 18 years) provided assent, and parent or guardian informed consent was obtained.
: Not applicable.
: The authors report the following competing interests: Peter L Anderson reports grants from Gilead; and consulting fees from Gilead, Merck, and ViiV Healthcare. Connie Celum reports grants to her institution from the NIH and the Bill & Melinda Gates Foundation; consulting fees from Merck and Gilead as a scientific advisor; payments for expert testimony and support for attending meetings from Gilead; and donated drugs from Gilead. Geetha Beauchamp, Deborah Donnell, Sybil Hosek, Kwun C. G. Chan, Bonnie J. Dye, Nyaradzo Mgodi, Linda-Gail Bekker, and Sinead Delany-Moretlwe have no competing interests to report.